Commercialisation of the bio-therapeutic resolution agent HYPER-DS-sIL-6R. (360G-Wellcome-079044_Z_06_A)
The increased incidence of antibiotic resistant bacterial strains such as MRSA and VRSAover the past few years has identified the necessity for development of alternative therapeutic strategies. Professor Nicholas Topley and Dr Simon Jones at the University of Wales have been awarded translational funding to further develop a therapeutic to supplement the body's existing defence system to help clear various types of bacterial infection.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
Amount Awarded | 109851 |
Applicant Surname | Topley |
Approval Committee | Technology Transfer Challenge Committee |
Award Date | 2009-06-08T00:00:00+00:00 |
Financial Year | 2008/09 |
Grant Programme: Title | Translation Award |
Internal ID | 079044/Z/06/A |
Lead Applicant | Prof Nicholas Topley |
Partnership Value | 109851 |
Planned Dates: End Date | 2009-12-31T00:00:00+00:00 |
Planned Dates: Start Date | 2007-01-01T00:00:00+00:00 |
Recipient Org: Country | United Kingdom |
Region | Wales |